Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

id: 359866
Source ↗ · id

opportunityNumber: FOR-TR-27-002
Source ↗ · opportunityNumber

opportunityTitle: Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
Source ↗ · opportunityTitle

revision: 0
Source ↗ · revision

agencyDetails: {"code":"NIH","seed":"HHS-NIH11","agencyName":"National Institutes of Health","agencyCode":"HHS-NIH11","topAgencyCode":"HHS"}
Source ↗ · agencyDetails

owningAgencyCode: HHS-NIH11
Source ↗ · owningAgencyCode

cfdas: [{"id":430015,"opportunityId":359866,"cfdaNumber":"93.350","programTitle":"National Center for Advancing Translational Sciences"}]
Source ↗ · cfdas

forecastDesc: <p>The&nbsp;National Center for Advancing Translational Science (NCATS) seeks to advance its mission by&nbsp;advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.</p><p><br></p><p>The main objective of this program,&nbsp;<strong>Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)</strong>, is to support&nbsp;the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.</p><p><br></p><p>Areas of interest for ExTReMe could include, but are not limited to:</p><ol><li>direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);</li><li>designer EVs (personalized to the individual patient’s needs).</li></ol><p><br></p><p>Grant authorities that allow the&nbsp;National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network</p>
Source ↗ · forecastDesc

applicantTypes: [{"id":"12","description":"Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"06","description":"Public and State controlled institutions of higher education"},{"id":"01","description":"County governments"},{"id":"05","description":"Independent school districts"},{"id":"23","description":"Small businesses"},{"id":"11","description":"Native American tribal organizations (other than Federally recognized tribal governments)"},{"id":"08","description":"Public housing authorities/Indian housing authorities"},{"id":"00","description":"State governments"},{"id":"20","description":"Private institutions of higher education"},{"id":"07","description":"Native American tribal governments (Federally recognized)"},{"id":"22","description":"For profit organizations other than small businesses"}]
Source ↗ · applicantTypes

fundingInstruments: [{"id":"CA","description":"Cooperative Agreement"}]
Source ↗ · fundingInstruments

fundingActivityCategories: [{"id":"HL","description":"Health"}]
Source ↗ · fundingActivityCategories

costSharing: false
Source ↗ · costSharing

lastUpdatedDate: Jun 27, 2025 04:30:53 PM EDT
Source ↗ · lastUpdatedDate

status: forecasted
Source ↗ · oppHits[id=359866].oppStatus